Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHASIT: Sequential Chemo-Immunotherapy in Locally Advanced Urothelial Cancer
NCT05600127Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2022
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in urothelial carcinoma (UC), sponsored by Erasmus MC. Started Dec 2022; status: recruiting.
02
Drugs
avelumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05600127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600127.